Daily Program
NB: Please check program on site in case of last minute changes.
Time slots in blue text indicate Company Presentations. Click on company name to view abstract.
Opening Session
09:30-10:00 Welcome by Conference Chairpersons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, Orbimed Advisors
10:00-10:40 Robert C. King, PhD, Partner at Goldman Sachs International and Global Vice Chairman, Investment Banking Division: “Current Developments in Healthcare Capital Markets and M&A”
10:40-11:20 Barry Greene, President, Alnylam Pharmaceuticals: “Nobel Prize-Winning Science to First Approved RNAi therapeutic”
Coffee Break
Gene Editing and Gene Therapy: The Next Frontier in Human Health
Co-chairs: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; Stephen Squinto, PhD, Interim CEO, Passage Bio
11:50-11:55 Opening by Co-chairs
11:55-12:20 Adi Barzel, PhD, Senior Lecturer, Department of Biochemistry at Tel Aviv University; Co-Founder of LogicBio Therapeutics, Inc.; President of the Israeli Society of Gene and Cell Therapy: “Principles of Gene Editing; CRISPR in B Cells Fighting AIDS”
12:20-12:40 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Novel Approaches for Antibody-targeted Intracellular Delivery of Large Nucleic Acids incl. CRISPR Mediated Gene Editing Modules”
12:40-13:00 Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco: “CRISPRa Therapeutics for Haploinsufficient Disease”
13:00-13:20 Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
13:20-13:35 Kyle Chiang, PhD, VP Product Strategy, LogicBio Therapeutics: “In Vivo Genome-editing for Rare Pediatric Diseases”
13:35-13:50 David Baram, PhD, Chief Executive Officer, Emendo Bio Inc: “Emendo Biotherapeutics – High Precision Gene Editing with Next Generation CRISPR Nucleases”
13:50-15:20 Lunch Break
15:20-15:45 Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College: “Gene Therapy for CNS Disorders”
15:45-16:05 Stephen Squinto, PhD, Interim CEO, Passage Bio: “Passage Bio: Developing Transformative Genetic Medicines for Rare Monogenic CNS Diseases”
16:05-16:25 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; “Using Gene Therapy for the Treatment of Rare Genetic Liver Disease”
16:25-16:40 Trevor Martin, PhD, CEO and Co-Founder, Mammoth Biosciences: “The Next Generation of CRISPR Tools”
16:40-16:55 Dalia El-Ani, PhD, Chief Executive Officer, CRISPR Stem & Therapeutics: “CRISPR: A Novel Gene Therapy to Protect the Heart from Acute Ischemic Damage”
16:55-17:40 “Panel Discussion
Panelists:
Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College
Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco
Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Stephen Squinto, PhD, Interim CEO, Passage Bio
Transforming Medicine: Artificial Intelligence and Digital Health
Co-chairs: Anat Naschitz, Managing Director, OrbiMed Advisors; Allen Kamer, Managing Partner, OurCrowd Qure
11:50-11:55 Opening by Co-chairs
11:55-12:20 Don Mathis, General Manager, Growth, Comcast NBCUniversal: “Changing Healthcare at Scale: How AI is Enabling Transformation”
12:20-12:45 Elliot Menschik, MD, PhD, Global Head Healthcare and Lifescience Startups, Amazon: “Democratizing AI/ML Capabilities and Accelerating their Impact on Healthcare”
12:45-13:00 Leif E. Pedersen, CEO, Dassault Systemes BIOVIA: “Real Life Examples of BioPharma Leveraging AI and Machine Learning”
13:00-13:15 Doron Behar, MD, PhD, CEO, Igentify: “An End-to-end & Scalable Digital Platform Designed for Web-assisted Genetic Counselling”
13:15-13:30 Yaron Gurovich, CTO, FDNA: “Hype vs. Hope: Using AI to Detect Disease”
13:30-13:45 Itay Bengad, CEO, MDGO: “Your Car Knows your Injuries”
13:50-15:20 Lunch Break
15:20-15:40 Avinatan Hassidim, Head of TLV Research, Google: “How Google uses Machine Learning for Medical Research”
15:40-15:55 Ziv Ofek, Founder and CEO, MDClone: “Democratizing Healthcare Data – today and Tomorrow”
15:55-16:10 Hadas Bitran, Head of Healthcare Israel, Microsoft: “Microsoft – Healthcare Innovation”
16:10-16:25 Tamara Mansfeld, Global Innovation Lead, Pfizer: “AI in Drug Discovery”
16:25-16:40 David Harel, Founder and CEO, CytoReason: “Machine Learning for Drug Discovery and Development”
16:40-16:55 Avi Veidman, Founder and CEO, Nucleai: “Harnessing AI for Pathology”
16:55-17:10 Ariel Beery, Founder and CEO, MobileODT: “Using Augmented Reality at the Point of Care to Eliminate Cervical Cancer”
17:10-17:25 Micah Pearlman, COO, Biolojic Design: “Making the Intractable Tractable: Designing Multi-Functional, Epitope Specific Antibodies using Machine Learning”
Disruptive and Advanced Medical Devices
Co-chairs: Irit Yaniv, MD, General Partner, Accelmed; Ron Ginor, MD, Venture Partner, OrbiMed Advisors, L.L.C
11:50-11:55 Opening by Co-chairs
11:55-12:10 Bruce R. Rosengard, MD, VP, Global External Innovation, Johnson and Johnson Medical Devices: “Market Perspective”
12:10-12:25 Oren Goldshtein, Vectorius Medical Technologies: “Transforming Heart Failure Treatment with the World’s First In-heart Microcomputer”
12:25-12:40 Ofri Vaisman, COO, Bluewind Medical: “Bluewind Medical Renova System – Neurostimulation Therapy for Over Active Bladder”
12:40-12:55 Ron Aginsky, President, FUSMobile: “Non-Invasive Procedure for Interventional Pain Managment Treatment”
13:00-13:15 Nicholas Pachuda, WW Vice President, Orthopedic Innovation, J&J Medical Devices: “Field Specific – Orthopedics”
13:15-13:30 Yehiel Tal, CEO, Collplant Ltd, “rhCollagen – the Ideal Building Block for Regenerative Medicine”
13:30-13:45 Boaz Behar, CEO, Digma Medical: “Restoring Glycemic Control in Patients with T2D”
13:50-15:20 Lunch Break
15:20-15:35 John J. Smith, MD, Partner, Hogan Lovells: “Regulatory Perspective”
15:35-15:50 Nitai Hanani, CEO, Paragate Medical: “Implantable Peritoneal Ultrafiltration Device for Fluid Overload Treatment”
15:50-16:05 David Israeli, CEO, Magenta Medical: “Minimally-Invasive Blood Pumps for the Treatment of Acute Heart Failure”
16:05-16:20 Prof. Joel V. Brill, MD, FACP, Chief Medical Officer, Predictive Health. LLC: “Reimbursement Perspective”
16:20-16:35 Yoram Solberg, MD, PhD, VP Clinical Affairs, Brainsgate: “Spheno Palatine Ganglion Stimulation for Treatment of Acute Ischemic Stroke”
16:35-16:50 Nathalie Gilat, Senior Director, Nyxoah: “Nyxoah – Sleep Apnea Healthtech Company”
16:50-17:05 Shai Policker, Medex Exlerator, “Incubator Perspective”
17:05-17:20 Eric Tansky, Managing Director, Oppenheimer & Co. Inc.: “Funding Perspective”
17:20-17:25 Closing by Co-chairs
Plenary Session
09:30-09:50 Amy W. Schulman, Managing Partner, LS Polaris Innovation Fund and Polaris Partners: “Building Early Stage Companies within the Biotech Ecosystem: Challenges and Opportunities”
09:50-10:10 Aharon Aharon, CEO, Israel Innovation Authority: “Bio-convergence – the Future of Israeli Healthtech”
10:10-11:00 Corporate Panel: Innovative Biotech/Large Companies/Capital: What’s the Right Formula to Bring Products to Patients?
Moderator: Francois Maisonrouge, Senior Managing Director, Evercore Partners
Panelists:
Fiona de Hemptinne, Venture Partner, UCB Ventures
Miriam Frieden, PhD, MBA, VP of Search and Evaluation, Novo Nordisk
Laurent Choppe, DVM, Managing Partner, Cukierman & Co. Life Sciences
Zafrira Avnur, PhD, CSO & Partner, VP Quark Venture Inc.
Tina Xu, Vice President of Information Technology and Head of Business Innovation, AstraZeneca China
11:00-11:40 Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences: “Investing in Innovation”
Coffee Break
Prevention and Rehabilitation: Should the Underdog Begin Barking?
Chair: Naomi Gefen, Deputy Director General, ALYN Hospital
Opening Session
12:10-12:25 Maurit Beeri, MD, Director General, ALYN Hospital: “From Prevention to Rehabilitation”
12:25-12:45 Yoav Medan, PhD: “The Technology Augmented Homo Sapiens“
Circle of Life: Prevention and Rehab for all ages
12:45-13:05 Sagit Arbel-Alon, MD, Deputy Director, Reuth Medical & Rehabilitation Hospital: “Geriatric Rehabilitation”
13:05-13:20 Rafi Fischer, Director of Media Communications, OrCam Technologies: “OrCam Technologies – AI-Driven Artificial Vision”
13:20-13:35 Or Retzkin, CEO & Co-founder; EyeControl: “EyeControl: Inspiring Communication”
13:35-13:55 Itamar Offer, MD, MPA, CEO, Sabar Health: “Rehabilitation at Home”
13:55-14:10 Yotam Drechsler, CEO, BrainQ technologies: “BCI Based Stimulation Device- BQ (BrainQ technologies)”
14:10-15:40 Lunch Break
15:40-15:55 Maurit Beeri, MD, Director General, ALYN Hospital: “Pediatric Rehabilitation”
15:55-16:10 Yotam Bahat, CEO, SENSERUM: “SENSERUM – VR for Clinical Use”
Taking Rehab to Another Level – Enabling Meaningful Participation in the Community and Workplace
16:10-16:25 Daniel Barel, CEO, SoftWheel: “SoftWheel – Innovative Technology for Mobility Solutions”
16:25-16:50 Yaron Galitzky, General Manager, Devices & Accessories, Microsoft; “Xbox Adaptive Controller”
16:50-17:15 Ziv Shilon, Co-founder, COO, 6Degrees: “Be the Hero of your Own Story”
Closing Session:
17:15-17:25 Naomi Gefen, Deputy Director General, ALYN Hospital: “The Future of Technology in Rehab”
Tango of the Two: Academia and Industry
Co-chairs: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University; Yaron Daniely, PhD, CEO, Yissum
12:10-12:30 Jeroen Tas, Chief Innovation & Strategy Officer, Philips
12:30-12:45 Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem: “Sensor-driven Leap in Drug Development on a Chip”
12:45-13:00 Arnaldo Mayer, PhD, VP, R&D, Voxellence: “Voxellence: AI-powered Radiology”
13:00-13:15 Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University: “Monitoring Sleep Stages at Home”
13:15-13:45 Panel discussion: Lessons Learnt by Researchers
Moderator: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University
Panelists
Prof. David Mirelman, PhD, Weizmann Institute of Science
Prof. Gal Markel, MD, PhD, Tel Aviv University
Prof. Daniel Offen, PhD, Tel Aviv University
Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem
13:45-14:00 Eran Stark, MD, PhD, Sackler Faculty of MedicineTel Aviv University: “Penetrating Neural Probes”
14:00-14:15 Giora Davidovits, President and CEO, Savicell: “A Revolutionary Liquid Biopsy, Immunometabolism Platform for High Accuracy, Early Stage Diagnosis of Diseases”
14:10-15:40 Lunch Break
15:40-15:55 Prof. Tal Dvir, PhD, Tel Aviv University: “Printed Heart”
15:55-16:10 Tomer Behor, CEO, RenewSenses: “RenewSenses – Conveying Vision Through Sound”
16:10-16:25 Chen Levin, CEO, Xact Robotics Ltd: “XACT Robotics – XACTly on Target Every Time”
16:25-16:40 Uzi Sofer, Alpha TAU Medical: “First Alpha-radiation Cancer Treatment for Solid Tumors”
16:40-16:55 Tamar Ben-Yedidia, PhD, CSO, BiondVax Pharmaceuticals Ltd: “Update of the Pivotal, Clinical Efficacy, Phase 3 trial of BiondVax’s M-001 Universal Influenza Vaccine”
16:55-17:45 Panel Discussion: It Takes a Village: Boosting the Volume and Quality of Academic Entrepreneurship
Moderator: Yaron Daniely, PhD, CEO, Yissum
Panelists:
Aviv Zeevi, PhD, VP, Technology Infrastructure Division, Israel Innovation Authority
Kelly Krajnik, Senior Manager, Devices, Diagnostics, Mayo Clinic Ventures
Regine Shevach, Managing Director at Inter-Lab, an affiliate of Merck KGaA
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon
Shai Policker, CEO, Medex Xelerator LP
New Modalities of Cell Therapies: Revolutionizing the Way We Treat Diseases
Co-chairs: Aya Jakobovits, PhD, Founder, Director, Adicet Bio; Erez Chimovits, Senior Managing Director, OrbiMed Advisors
12:10-12:15 Opening remarks by Co-chairs
12:15-12:40 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Adoptive Cell Therapy 3.0”
12:40-13:05 Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors: “The Cell Therapy Field has already Generated some of the Best Returns in Biotechnology, and the Best is Yet to Come, Based on Enhanced Cell Therapy Technologies”
13:05-13:20 Prof. Angel Porgador, PhD, Ben-Gurion University: “Natural Killer (NK) Cells in Cancer Immunotherapy”
13:20-13:35 Michal J. Besser, PhD, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology & Director, Wohl GMP Facility, Sheba Medical Center; Assistant Professor, Dept. of Microbiology and Immunology, School of Medicine, Tel Aviv University: “Clinical Experience with In-house Produced CAR T Cells”
13:35-13:50 Stewart Abbot, PhD, Chief Operating Officer, Adicetbio: “Off-the-shelf, Engineered Gamma Delta T-cell Therapies”
13:50-14:05 Merav Beiman, PhD, CEO, ImmPACT-Bio: “Next Generation CAR-T Engineering Solving the ‘On-Target’ ‘Off-Tumor’ Issue towards Broader, Safer and Effective CAR-T Therapies”
14:05-14:10 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Session #1 Summary”
14:10-15:40 Lunch Break
15:40-15:55 Yoav Ben Ya’acov, CEO, CTG Pharma: “CTG Pharma- Safe CAR T Therapy for Solid Tumors”
15:55-16:10 Amy W. Schulman, Executive Chair, SQZ Therapeutics: “SQZ Biotech: Unleashing the Power of Cells”
16:10-16:25 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex- vivo Expansion of Natural Killer (NK) Cells to Treat B-Cell Lymphoma and Multiple Myeloma”
16:25-16:40 Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD: “Enilvex Therapeutics, Immune Rebalancing”
16:40-17:40 Panel Discussion: “The Path for Effective and Accessible Cancer Cell Therapy”
Panelists:
Amy W. Schulman, Executive Chair, SQZ Therapeutics
Aya Jakobovits, PhD, Founder, Director, Adicet Bio
Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors
Stewart Abbot, PhD, Chief Operating Officer, Adicet
Julian Adams, PhD, Chief Executive Officer, Gamida Cell
Plenary Session
09:30-10:10 Tom Sudow, Director, Business Development, Cleveland Clinic Innovations; Mark D. Stovsky, MD, MBA, FACS, Senior Director, Emerging Business, Cleveland Clinic Ventures: “The Revolutionary Changes in Healthcare Delivery: From Prevention to Rehabilitation and Everything in Between”
10:10-10:50 Jeroen Tas, Chief Innovation & Strategy Officer, Philips: “Creating the Future of Healthcare Through Digital Innovation”
Coffee Break
Transformative Cancer Therapies
Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund
11:20-11:25 Opening by Chair
11:25-11:50 Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc: “The 20 Year Journey of an Oncology Drug”
11:50-12:05 Prof. Elizabeth Croydon, Senior Clinical Director, Oncology – EU Clinical Development, Merck Sharp & Dohme: “MSD Immune-oncology Innovative Therapies”
12:05-12:20 Shoshi Tessler, R&D VP, BioSight: “Biosight Ltd. is Developing BST-236, a Novel Antimetabolite for First-line Treatment of Hematological Malignancies and Disorders”
12:20-12:35 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex Vivo Expanded Cells to Treat Hematological Malignancies”
12:35-12:50 Baruch Schori, Chief Executive Officer, PTM Biosciences: “PTM Biosciences is Promoting Precision Medicine by Transforming Post-Translational Modifications into Novel Therapeutic Targets and Biomarkers for Disease Management”
12:50-13:05 Tehila Ben Moshe, PhD, Chief Executive Officer & Co-Founder, Biond Biologics: “Biond Biologics: From Innovative Science to the Clinic; Transforming the Treatment of Cancer”
13:05-13:20 Israel Isaac, Chief Executive Officer, Kitov Pharma: “NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance”
13:20-14:50 Lunch Break
14:50-15:10 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Bi-Specific Antibodies and Fusion Proteins in Cancer Therapy”
15:10-15:25 Prof. Dror Harats, CEO, Vascular Biogenics: “Turning ‘Cold’ Tumor into ‘Hot’ Tumor – Lessons from VB-111, a Viral Immuno-oncology Agent and VB-611, a Novel Bi-specific Antibody”
15:25-15:40 Roni Mamluk, PhD, Chief Executive Officer, Ayala Pharmaceuticals: “Ayala Pharmaceuticals – Precision Oncology Targeted Therapy”
15:40-15:55 Frank Haluska, MD, PhD, Chief Executive Ofiicer, Anchiano Therapeutics: “Gene Therapy for Early Stage Bladder Cancer: The Pivotal Program with Inodiftagene”
15:55-16:10 Mark Schoenberg, MD, Chief Medical Officer, UroGen Pharma: “UroGen Pharma: Paradigm Changing Technology for Urologic Oncology”
16:10-16:25 Asher Nathan, CEO, NeoTX Therapeutics Ltd: “Selective T Cell Redirection (STR): A Second Generation Immunotherapy”
16:25-16:40 Amnon Peled, PhD, Chief Executive Officer, Biokine Therapeutics: “Development of First in Class High Affinity Small Molecule Antagonist of a Novel Cancer Target Critical for Tumor Cell Migration and Survival”
16:40-17:00 Concluding Remarks
Personalized Medicine and Digital Health: Lessons Learned and Challenges Ahead
Co-chairs: Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund; Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccab Research and Innovation Institute at Maccabi Health Care Services
11:20-11:40 Fireside Chat – The Future Doctor, Patient and In-between
Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccabi Research and Innovation Institute at Maccabi Health Care Services
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund
11:40-11:55 Oren Oz, CEO, Nuvo Group: “Reinventing Pregnancy Monitoring and Management for the 21st Century”
11:55-12:10 Seth Salpeter, CTO, Curesponse: “A Next Generation Platform for Definitive Treatment Answers in Personalized Cancer Medicine”
12:10-12:30 Michal Rozen-Zvi, Director, Healthcare Informatics, IBM Research: “Learn from Screening Data and Assessing Breast Cancer Risk”
12:30-12:45 Daniella Gilboa, Chief Scientific Officer and Co-Founder, AIVF: “Transforming IVF with the Power of Artificial Intelligence”
12:45-13:05 Uma Makhija, Business Development Lead, Digital Health, Otsuka Pharmaceuticals: “Pharma and Digital Therapeutics Partnerships – Opportunities and Challenges”
13:05-13:20 Lihi Segal, CEO, DayTwo: “Personalized Nutrition Recommendations for Normalizing Blood Glucose Levels Based on Microbiome, Medical and Personal Records”
13:20-14:50 Lunch Break
14:50-15:10 Prof. Eitan Friedman, MD, PhD, Director & Founder of The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center
15:10-15:25 Alex Melamud, CEO, Melcap Systems: “First Digital Health Affordable System for the Treatment of Overweight and Obesity for Billions”
15:25-15:40 Vince Gao, PhD, Founder & CEO, Govita Tech: “Association of Genetic and Metabolic Data Derived from Metabolic Pathways for Personalized Intervention of Chronic Diseases”
15:40-15:55 Erez Gavish, Co-Founder/CEO, 2breathe Technologies Ltd: “Can Digital Therapeutics Lower Sympathetic Overactivity?”
15:55-16:15 Elliot Menschik, MD, PhD, Global Head, Healthcare + Life Science Startups, Amazon Web Services: “Re:Inventing Healthcare – Glimpses of Digitally-enhanced, Data-driven Future”
16:15-16:30 Simona Di-Capua, Sr Dir GXR&D Tech & Process Design KFS, Teva: “3D Printing – A Novel Approach to Design and Manufacture Personalized Medicines”
16:30-16:45 Eyal Baum, Director of Strategic Accounts, Tyto Care: “Clalit Health Servics Expanding its Telemedicine Offering with TytoCare’s Physical Exam from Home”
16:45-17:05 Wade Ackerman, Partner, FDA Regulatory group, Co-Lead of Digital Health Initiative, Covington & Burling LLP: “Navigating the Evolving Regulation of Personalized Medicine and Digital Health”
Cannabis’ Therapeutic Promise: Hope or Hype?
Co-chairs: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem; Ayelet Torem, Adv, Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co
11:20-11:45 Dorman Followwill, Senior Partner, Frost & Sullivan: “Outlook for Cannabis as Therapeutic Agent”
11:45-12:05 Prof. Hinanit Koltai, PhD, Agricultural Research Organization (ARO), Volcani Center: “Medical Cannabis: from Weed to Molecules to Drug Development”
12:05-12:25 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Improvement of CBD and THC Oral Bioavailability using Nano Delivery Systems”
12:25-12:45 Yossi Tam, The Hebrew University of Jerusalem: “Cannabinoid-Based Therapies: Lessons Learned from the Endocannabinoid System”
12:45-13:10 Prof. Raphael Mechoulam, PhD, Hebrew University of Jerusalem: “Cannabinoids: A Look Back and Ahead”
13:20:-14:50 Lunch Break
14:50-15:10 Medy Wiener, MD, Chief Medical Officer, BOL Pharma: “Drug/Cannabinoid Clinical Development Route – Same but Different”
15:10-15:25 Prof. Oded Shoseyov PhD, Co-founder and CSO, GemmaCert Ltd: “Remote Sensing of Cannabis; The First Step towards Standardization and Closing the Learning Cycle”
15:25-15:40 Tamir Gedo, CEO, BOL Pharma: “The Winners and Losers of the Global Cannabis Industry”
15:40-15:55 Ascher Shmulewitz, CEO, Therapix Biosciences Ltd: “Therapix Biosciences Developing Cannabinoids of the Future”
15:55-16:10 Perry Davidson, CEO, Syqe Medical Ltd: “Medical Cannabis – The Green Elephants in the Room”
16:10-16:25 Dadi Segal, CEO, Panaxia Pharmaceutical Industries Ltd: “Panaxia – Manufacturing of Pharmaceutical Cannabis Products”
16:25-16:40 Taher Nassar, VP, Research, Bionanosim Ltd: “Bionanosim Ltd-Innovative Nano-Carriers for Improved Cannabis-BNS”
16:40-17:00 Prof. Itamar Raz, MD, Head, The Israeli National Diabetes Council: “Medical Cannabis treatment of Pain and Glycemic Control”
17:00-17:20 Ayelet Torem, Adv., Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co: “Medical Cannabis Regulatory Overview”